

## Global experience and expertise in rheumatoid arthritis clinical trials

Synarc scientists pioneered many of the imaging and biochemical markers used in clinical trials of rheumatoid arthritis. We currently manage 12 multicenter trials in rheumatoid arthritis, involving more than 5,000 patients at over 600 global sites.

### Cutting-edge imaging and comprehensive clinical-trial services

Synarc leads the way in imaging assessment of rheumatoid arthritis in global, multicenter clinical trials. Our services integrate all aspects of the design and execution of these studies, and provide a broad panel of imaging and biochemical markers for quantifying disease severity and progression.

Our expertise and experience can improve the efficiency of your clinical trial and reduce the uncertainty and cost of therapeutic development. Contact us to discuss how.



### Advanced MRI services

Synarc performed the first large multicenter clinical trial in rheumatoid arthritis using MRI, and helped develop the MRI scoring method recommended by EULAR and OMERACT. Our MRI services expand the scope of structural assessment, allowing better decision making earlier in your therapeutic development program.

### Established x-ray services

The Genant-modified Sharp scoring method was developed by Synarc founding scientists. It has been used in multiple clinical trials, and it helped gain regulatory approval for Orenzia® (abatacept) as well as for Rituxan® (rituximab) and MabThera® (rituximab) for use in rheumatoid arthritis. Synarc also conducts clinical trials using other methods, including van der Heijde-modified Sharp scoring.

### Synarc optimized image acquisition and analysis

#### Syn-X-RA™ Positioning Frame and Phantom

Ensures reproducible positioning of the hands and feet for radiography and prevents left-right mislabeling and variations in x-ray beam centering.

#### SynaVu™ Digital X-ray and MRI Reading System

Provides 21 CFR Part 11 compliant patient-grouped display and analysis of images with masking of patient, treatment, and chronological information. SynaVu also allows quantitative assessment of synovitis dynamic contrast-enhanced MRI.



Orenzia is a registered trademark of Bristol-Myers Squibb Company. Rituxan is a registered trademark of Biogen Idec, Inc. MabThera is a registered trademark of Hoffman La-Roche, Inc.



### Imaging-Marker Services

- X-ray
  - Modified Sharp scoring
- MRI
  - Erosion, osteitis, and synovitis scoring
  - Quantitative assessment of synovitis

### Biochemical-Marker Services

- Bone degradation
- Bone formation
- Regulators of osteoclastic and osteoblastic activity
- Cartilage degradation
- Cartilage synthesis and turnover
- Synovial activity
- Matrix-metalloproteases
- Serum ultrasensitive C-reactive protein
- Cytokines/chemokines

For a complete list of biochemical-marker services, please contact your Synarc account executive.



